Viagra Blocks a Hidden Cholesterol Pathway in Cancer

A pill associated with late-night remedies might have quietly found a new stage: the tumor microenvironment. Surprising? Yes. Plausible? The data say so.

Researchers at the Weizmann Institute discovered that sildenafil—the active ingredient in Viagra—can interrupt an internal route cancer cells use to commandeer cholesterol. That lipid is a scaffold for cell membranes and becomes vital when tumor cells break away, travel through the bloodstream and seed distant organs. Take that scaffold away, and metastasis loses some of its momentum.

The mechanism is clever and indirect. Sildenafil blocks the enzyme phosphodiesterase type 5 (PDE5), which raises levels of the signaling molecule cGMP. Everyone knows that cGMP relaxes blood vessels, explaining the drug’s erectile effect. What this team showed is that cGMP also binds to a protein that ferries cholesterol inside cells, effectively tying up transport so less cholesterol reaches where invading cancer cells need it.

Short version: cholesterol becomes scarce. Cancer cells hate scarcity. They are especially vulnerable when they must rebuild membranes during invasion and colonization. In lab dishes and in mice, interfering with this cholesterol shuttle reduced the capacity of cancer cells to spread.

The story gets more interesting with statins—the widely used medicines that block new cholesterol production. When sildenafil-like drugs and statins were combined, the researchers observed a two-pronged squeeze: less new cholesterol made and less of the existing cholesterol delivered where tumor cells want it. The combined pressure amplified the anti-metastatic signal in experimental models.

Evidence did not stop at cells and rodents. The study—published in Cancer Research—pulled in real-world medical records from Israel’s Clalit Health Services covering roughly five million people, together with clinical and experimental contributions from teams led by Prof. Eytan Ruppin and Prof. Shay Ben-Shachar and clinicians at Rabin Medical Center. Patterns in those records showed that cancer patients who had used sildenafil, particularly alongside statins, tended to survive longer than similar patients who had not.

“We found a new link between a classic signaling molecule and intracellular cholesterol control,” says Prof. Ayelet Erez, who led the work. She points out that the findings illuminate how a patient’s metabolism and the drugs they take for unrelated conditions can shape tumor behavior. Treat the body, not only the tumor, she suggests.

Existing drugs already in medicine cabinets might be repurposed to close a vulnerable route cancer cells depend on to spread.

Questions remain. Which cancer types are most sensitive? What doses and timing produce the best effect without unacceptable side effects? Large, controlled clinical trials will be required before physicians change practice. Still, the study offers a striking reminder: sometimes the next advance in cancer care hides inside familiar medicines—if we know where to look.